ALTERITY THERAPEUTICS LIMITED - AMERICAN DEPOSITAR

Appendix 4C – Q3 FY24 Quarterly Cash Flow Report

30 4 2024 06:25:00 提供 Nasdaq GlobeNewswire

Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia

29 4 2024 06:25:00 提供 Nasdaq GlobeNewswire

Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting

17 4 2024 06:25:00 提供 Nasdaq GlobeNewswire

Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024

10 4 2024 06:25:00 提供 Nasdaq GlobeNewswire

Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund

26 3 2024 09:25:00 提供 Nasdaq GlobeNewswire

Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting

20 2 2024 09:25:00 提供 Nasdaq GlobeNewswire

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

06 2 2024 06:25:00 提供 Nasdaq GlobeNewswire

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week

29 1 2024 06:24:00 提供 Nasdaq GlobeNewswire

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

22 1 2024 06:25:00 提供 Nasdaq GlobeNewswire

Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer

20 12 2023 23:30:00 提供 Nasdaq GlobeNewswire

Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress

04 12 2023 15:35:00 提供 Nasdaq GlobeNewswire

Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease

04 12 2023 06:25:00 提供 Nasdaq GlobeNewswire

Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy

27 11 2023 06:25:00 提供 Nasdaq GlobeNewswire

Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434

16 11 2023 06:25:00 提供 Nasdaq GlobeNewswire

Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy

08 11 2023 06:25:00 提供 Nasdaq GlobeNewswire

Appendix 4C – Q1 FY24 Quarterly Cash Flow Report

30 10 2023 06:25:00 提供 Nasdaq GlobeNewswire

Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder

31 8 2023 06:25:00 提供 Nasdaq GlobeNewswire

Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson’s and Alzheimer’s

23 8 2023 06:25:00 提供 Nasdaq GlobeNewswire

Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson’s Disease and Movement Disorders

22 8 2023 06:25:00 提供 Nasdaq GlobeNewswire

Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund

15 8 2023 06:25:00 提供 Nasdaq GlobeNewswire